SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

“People living with diabetes are benefiting from our Control-IQ technology across diverse populations and therapeutic backgrounds, which supports our mission to improve the lives of people living with ...

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference on ...

Positive clinical trial results for the Control-IQ algorithm from Tandem Diabetes Care presented at the American Diabetes Association meeting earlier this month positions the company to continue its ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

Tandem Diabetes (TNDM 8.70%) today announced the commercial launch of the newest version of its flagship insulin pump in the U.S. market. The company's signature t:slim X2 insulin pump will also now ...

The FDA approved its first automatic insulin dosing system designed to deliver correction boluses as well as adjust background insulin levels to help prevent bouts of high and low blood sugar in ...

Tandem Diabetes Care has already proven that its closed-loop system for automated insulin delivery can improve the amount of time spent in range for people of all ages with Type 1 diabetes, but a new ...

A new software system that will let people with diabetes customize their treatment and automatically adjust their insulin levels was just approved for use by the Food and Drug Administration. It will ...